ALK FISH Positivity and Crizotinib Efficacy in ALK-Positive Patients With NSCLC.
This pooled analysis was designed to evaluate the correlation between extent of ALK FISH positivity and efficacy of crizotinib among patients with non–small cell lung cancer. ALK-positivity above 15% was associated with crizotinib response. In clinical trials of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) treated with crizotinib, evaluation of the relationship […]
ALK FISH Positivity and Crizotinib Efficacy in ALK-Positive Patients With NSCLC. Read More »
